Prior to randomisation, eligible patients discontinued their
diabetes treatment except for metformin, and were switched
from their prior insulin treatment to IDegAsp or BIAsp 30.
Stratification was performed according to previous insulin
regimen and metformin treatment at screening. Patients
were randomised (2:1) to twice daily injections of IDegAsp
(70% IDeg and 30% IAsp; Novo Nordisk A/S, Bagsværd,
Denmark; 100 U/mL) or BIAsp 30 (NovoMix 301, Novo Nordisk
A/S; 100 U/mL), both with or without metformin, for 26
weeks. This unequal randomisation was to be performed in
order to ensure an adequate number of subjects were
exposed to IDegAsp across the entire clinical program for
subsequent secondary analyses. The trial design could not be
blinded and was therefore open-label, since in contrast to
IDegAsp, BIAsp 30 requires re-suspension prior to injection.
Patients were switched to biphasic human insulin 30 at the
last treatment visit (Week 26) until the follow-up visit (Week
28). The rationale for the switch is that biphasic human
insulin 30 is a human insulin and consequently possible
interference with antibody measurements was reduced at
the follow-up visit